Primary Axillary Hyperhidrosis (PAH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Primary Axillary Hyperhidrosis (PAH) Market Outlook

Thelansis’s “Primary Axillary Hyperhidrosis (PAH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Primary Axillary Hyperhidrosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Primary Axillary Hyperhidrosis (PAH) Overview

Primary axillary hyperhidrosis (PAH), characterized by excessive sweating in the underarm area, is a distressing condition that profoundly impacts one's social and psychological well-being. It is the most common form of hyperhidrosis and typically begins before age 25. This condition may be inherited as an autosomal dominant genetic disorder with incomplete penetrance. It can manifest in various body parts, including the underarms, palms, groin, chest, and feet. The underlying cause of primary hyperhidrosis is the hyperactivity of the hypothalamic thermoregulatory center, which controls the eccrine sweat glands in the brain. This overactivity is transmitted to the eccrine sweat glands through the sympathetic nervous system. Several treatment modalities are available for PAH, such as using antiperspirants, systemic anticholinergic medications, laser procedures, and surgical interventions, such as sweat gland removal through excision, liposuction, curettage, and laser surgery. There are FDA-approved Glycopyrronium tosylate (GT). 2.4% of cloth is approved for patients nine and older. In contrast, OnabotulinumtoxinA is approved for severe cases of primary axillary hyperhidrosis. Additionally, BOTOX injections are approved by the FDA for individuals with axillary hyperhidrosis that is not adequately managed with topical agents.

• Hyperhidrosis is a condition that affects approximately 3% of the population, with an estimated prevalence of 2.8% in the United States, equating to around 7.8 million people. Among those with hyperhidrosis, 50.8% report experiencing axillary hyperhidrosis, affecting approximately 1.4% of the entire U.S. population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: